B2B healthcare marketers are having a good year. Revenue is up. Goals are getting beat. Buying groups are paying off. And somehow, this same group just got the smallest budget bump of any industry we surveyed. Nearly one in three saw their budget cut outright.
That's not bad luck. It's a gap between results and proof, and it's fixable.
Our 2026 B2B Marketing Edge research, healthcare edition, surveyed marketers selling to healthcare companies across the US, UK, and APAC. Here's what stood out: 37% of B2B healthcare marketers saw significant revenue growth, compared to 28% of marketers overall. They were also more likely to significantly exceed their marketing goals, 33% versus 28% industry-wide. And 43% have fully implemented buying groups, ahead of the broader market, with higher win rates as the top payoff.
By any normal measure, that's a team doing its job well.
So why did only 58% get a budget increase, the lowest of any industry we track? Why are healthcare marketers less confident than almost anyone else that their company's budget process actually makes sense? The report points to one culprit: measurement. Healthcare marketers are more likely to lean on proxy metrics instead of real ROI. They have a harder time seeing performance across channels in one place. They're less likely to know which activities are actually driving pipeline. Good work is happening. It's just not showing up in language a CFO trusts.
Numbers tell you what's happening. They don't always tell you how good teams solve it. So we asked Amanda Joyner, one of our sales leader who works healthcare accounts every day, what actually separates the demand generation programs that work from the ones that don't.
The pattern repeats itself across accounts. Compliance review is heavy. Internal contact lists are usually too thin to build a full campaign on. And the instinct to target a narrow physician title almost always leaves budget on the table.
"You have to supplement the audience," Amanda said. "Most healthcare clients don't have enough of their own data, so you need to strategically fill the gap, extending outreach to the actual buying committee. And once you open targeting up to the adjacent roles, the practitioners and staff around your core buyer, you're actually reaching the influencers who move the deal anyway."
That's the buying group principle playing out in real time. The report shows 43% of healthcare marketers have leaned into this fully, and the win-rate lift is why.
Channel mix matters too. Email is often the first thing to get cut in healthcare, since copy approval and suppression lists take internal bandwidth clients don't always have, and attribution is harder to prove. That budget tends to shift toward content syndication and HCP programmatic instead, channels that can run with less hands-on lift from the client. It's a smaller decision, but it echoes a bigger theme in the data: healthcare marketers are the most likely of any industry to have leaned harder into marketing-attributed revenue in the past two years. They're getting more deliberate about where a dollar actually earns its keep.
Events are part of the mix as well. Geofencing and retargeting around the industry conferences a physician audience actually attends works well precisely because that audience is so specific. You don't need broad reach. You need to be present where your buyer already is.
"You usually have to loosen the targeting a bit around events," Amanda said. "The audience narrows fast once you add location and timing on top of specialty, so you widen the net just enough to make sure you're not missing key people."
Done well, this kind of program regularly runs retargeting results above industry benchmarks. And the creative doesn't need to be flashy to get there. Compliance-conscious healthcare clients often keep it simple by necessity, minimal copy, nothing risky, and that restraint tends to work in their favor. A physician skimming between patients doesn't need a flashy ad. They need a clear one.
This is exactly what our healthcare report findings point to. Nearly half of healthcare marketers cite unreliable data as their top challenge, and 44% cite compliance requirements right behind it. Those aren't excuses. They're the terrain. The teams that win treat compliant, verified data and healthcare-specific expertise as a differentiator, not a hurdle. Anteriad is certified by Neutronian as a top 1% B2B data provider for quality and transparency, and clients using Neutronian-certified audiences see 52% higher click-through rates and 52.5% lower cost per acquisition than non-certified data. That's not a nice-to-have. In a regulated industry, it's the price of entry.
Campaign optimization is the other lever. 53% of healthcare marketers say approval processes slow their ability to move budget, and 55% say their tech stack won't let them adjust in real time. Fixing that internally matters, but so does the CFO conversation. The more clearly marketing can connect spend to pipeline, the easier it is to defend the budget that strong results already earned.
Healthcare B2B marketing isn't underperforming. It's under-proven. Clean data, wider buying group targeting, and campaigns built around where your audience actually shows up, that's the playbook, and it's already working for teams bold enough to run it. The next step is making sure the results speak a language finance can't ignore.
Ready to build a program that proves itself? Talk to our healthcare team about data, targeting, and full-funnel execution built for the way this industry actually buys.